MP84-15 PREVENT METASTASIS BY DOUBLE CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CIRCULATING CANCER CELLS FOR PROSTATE CANCER TREATMENT

Wujiang Liu,Weidong Han,Liqun Zhou,Yinglu Guo
DOI: https://doi.org/10.1016/j.juro.2016.02.2239
2016-01-01
Abstract:You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology III1 Apr 2016MP84-15 PREVENT METASTASIS BY DOUBLE CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CIRCULATING CANCER CELLS FOR PROSTATE CANCER TREATMENT Wujiang Liu, Weidong Han, Liqun Zhou, and Yinglu Guo Wujiang LiuWujiang Liu More articles by this author , Weidong HanWeidong Han More articles by this author , Liqun ZhouLiqun Zhou More articles by this author , and Yinglu GuoYinglu Guo More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2239AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Chimeric Antigen Receptor transfected T cells (CART) has significant anti-tumor effect in blood malignant tumor, but its effect on solid tumor remains challenge. In this study, we found that prostate cancer circulating cancer cells (CTC) specifically expressed EPCAM (Epithelial Cell Adhesion Molecule) and EMP2 (Epithelial Membrane Protein 2) in blood. EPCAM-CART and EMP2-CART combination can specificlly kill CTCs but not other cells in blood, thus stop blood metastasis. METHODS CTC was isolated from blood of prostate cancer patients with bone metastasis under informed consent. Total RNA was isolated from CTCs and PBMC (peripheral blood mononuclear cell). mRNA and protein level of EPCAM and EMP2 were assayed by real-time PCR, Western-blot and flowcytometry. The specific killing in vitro was assayed by co-culture CART cells with CTCs or PBMC. The effect on metastasis in vivo was tested on established PC3-M prostate cancer animal model. RESULTS EPCAM and EMP2 abundantly expressed on CTCs while not other cells in blood. The combination of EPCAM-CART and EMP2-CART significantly increase the killing capability than either EPCAM-CART or EMP2-CART alone on CTCs (P<0.01). Intravenous infusion the combination of EPCAM-CART and EMP2-CART effectively stop the lung metastasis on established PC3-M prostate cancer model. CONCLUSIONS EPCAM and EMP2 could be new immunotherapy targets of prostate cancer. Double chimeric antigen receptor T cells targeting circulating cancer cells can effectively prevent and stop the cancer metastasis. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e1095 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Wujiang Liu More articles by this author Weidong Han More articles by this author Liqun Zhou More articles by this author Yinglu Guo More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
What problem does this paper attempt to address?